RepliCel Life Sciences Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a REPCF research report →
Price Chart
About the company
RepliCel Life Sciences Inc. , a biotechnology firm based in Vancouver, Canada, specializes in regenerative medicine. The company focuses on developing patient-specific cell therapies designed to address functional cellular deficits.
- CEO
- Andrew Schutte
- IPO
- 2010
- Employees
- 1
- HQ
- Vancouver, BC, CA
Get TickerSpark's AI analysis on REPCF
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $7.36K
- P/E
- -9.38
- PEG
- 0.05
- P/S
- 3.12
- P/B
- -0.21
- EV/EBITDA
- -5.33
- Div Yield
- 0.00%
- Gross Margin
- 100.00%
- Op Margin
- -101.77%
- Net Margin
- -27.50%
- ROE
- 1.86%
- ROIC
- 49.90%
Latest fiscal year · YoY change
- Revenue
- $353.44K-0.1%
- Gross Profit
- $0-100.0%
- Op Income
- $237.84K
- Net Income
- $-401,629-312.8%
- EPS
- $-0.01-262.5%
- OCF Growth
- +44.2%
- FCF Growth
- +44.2%
- 52W High
- $0.04
- 52W Low
- $0.00
- 50D MA
- $0.00
- 200D MA
- $0.00
- Beta
- 0.56
- RSI (14)
- 54
- Avg Volume
- 23
No earnings-call transcripts are available for REPCF yet.
- Free Float
- 93.8%
- Shares Outstanding
- 73.57M
- Float Shares
- 69.03M
Our REPCF coverage
Recent articles, reports, and earnings notes.
No research on REPCF yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate REPCF report →RepliCel Files Notice of Arbitration against Shiseido Company to Resolve its License Agreement Dispute Regarding its Androgenetic Alopecia Cell Therapy
accesswire.com · Oct 18
RepliCel Life Sciences Appoints One of Japan's Foremost Regenerative Medicine Industry Business Leaders as Strategic Advisor
accesswire.com · Oct 12
RepliCel and University of Victoria Collaboration Leads to Bioengineering Innovations, Funding, and Patents
accesswire.com · Sep 16
RepliCel Applies for Manufacturing Approval for Its Collagen and Tissue Regeneration Cell Therapies
accesswire.com · Jul 7
RepliCel Adds Independent Director
accesswire.com · Jun 15
RepliCel Launches Preparations for Second Skin Rejuvenation and Tendon Regeneration Clinical Studies
accesswire.com · May 19
RepliCel Announces Record Year in Patents Granted
accesswire.com · May 5
RepliCel Announces Appointment of Leading Sports Medicine Expert as Orthopedics Clinical Advisor (Japan)
accesswire.com · May 3
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.